LivaNova Beats Q2 Estimates, Raises Full-Year Guidance on Strong Cardiopulmonary and Neuromodulation Growth
LIVN sits 82% above its 52-week low of $41.87.
Summary
LivaNova posted Q2 revenue of $390.6M (+10.8%), beating estimates, and raised full-year guidance. Net income surged to $108.6M, aided by a $95.4M tax benefit. The aura6000 sleep apnea device received FDA approval, and the company repaid its remaining term debt.
Key Events · Earnings and Guidance · LIVN
-
Q2 Revenue and EPS Beat
Revenue of $390.6M grew 10.8% reported, exceeding estimates. Diluted EPS of $1.93 compared to $0.50 in Q2 2025, driven by strong segment performance and a $95.4M discrete tax benefit.
-
Full-Year Guidance Raised
Management increased full-year 2026 revenue and EPS guidance, reflecting confidence in sustained growth across both Cardiopulmonary and Neuromodulation segments.
-
aura6000 FDA Approval and Milestone Payment
The FDA granted PMA for the aura6000 obstructive sleep apnea device in March 2026, triggering a $60.5M milestone payment to ImThera. The device addresses a large, underserved market.
-
Debt Repayment Strengthens Balance Sheet
The remaining $95.9M Term Facilities balance was repaid in January 2026, reducing total debt to $290.1M. Interest expense fell to $7.2M from $14.9M a year ago.
Analysis · LIVN · Industrial Applications And Services
LivaNova delivered a strong Q2 with revenue of $390.6 million, up 10.8% reported, beating consensus. Both segments grew double digits, driven by Essenz perfusion system sales and VNS Therapy volume. Management raised full-year revenue and EPS guidance, signaling confidence in sustained momentum. A $95.4 million discrete tax benefit from an Italian ruling on SNIA liability deductibility boosted net income to $108.6 million. The quarter also saw the FDA approval of the aura6000 OSA device, triggering a $60.5 million milestone payment, and the final $95.9 million repayment of term loans, strengthening the balance sheet. The only blemish was a higher 3T litigation provision, but the overall picture is one of accelerating operational performance and improving financial flexibility.
At the time of this filing, LIVN was trading at $76.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $41.87 to $85.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.